2023年，第59届美国临床肿瘤学会（ASCO）年会将于美国芝加哥当地时间6月2日至6日举行。4月26日，ASCO官网已公布了本次会议的日程和摘要题目。
【肿瘤资讯】整理了口头摘要专场（Oral Abstract Session）、临床科学研讨会（Clinical Science Symposium）壁报交流专场（Poster Discussion Session）的黑色素瘤研究，与读者分享。
口头摘要专场
摘要号：3008
蛋白质精氨酸甲基转移酶5 (PRMT5)脑渗透抑制剂PRT811用于复发性高级别胶质瘤或葡萄膜黑色素瘤(UM)患者中的I期研究
A phase 1 study of the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients (pts) with recurrent high-grade glioma or uveal melanoma (UM).
讲者: Varun Monga, MBBS | University of Iowa
摘要号：9501
在晚期黑色素瘤中使用fianlimab（抗LAG-3）和cemiplimab（抗PD-1）的显著持久缓解：辅助后PD-1分析
Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis.
讲者:Omid Hamid, MD | The Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate
摘要号：9502
纳武利尤单抗（NIVO）+relatlimab（RELA）vs NIVO治疗既往未经治转移性或不可切除黑色素瘤：RELATIVITY-047研究的2年结果
Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.
讲者：Hussein A. Tawbi, MD, PhD | University of Texas MD Anderson Cancer Center
摘要号：9511
达拉非尼和曲美替尼联合或不联合navitoclax治疗BRAF突变型（MT）转移性黑色素瘤（MM）患者（pts）的随机II期研究（CTEP P9466）
Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466).
讲者：Zeynep Eroglu, MD | H. Lee Moffitt Cancer Center and Research Institute
摘要号：LBA9503
来自随机、II期mRNA-4157-P201/KEYNOTE-942研究的无远处转移生存结果
Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.
讲者：Adnan Khattak, PhD, FRACP, MBBS | One Clinical Research and Edith Cowan University
摘要号：9504
在切除的IIB/C期黑色素瘤（CA209-76K）患者中生物标志物（BMs）与纳武利尤单抗（NIVO）vs 安慰剂（PBO）辅助治疗疗效的关联
Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).
讲者：Georgina V. Long, MD, PhD, FRACP | Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals
摘要号：LBA9505
帕博利珠单抗对比安慰剂作为IIB期或IIC期黑色素瘤的辅助治疗：III期KEYNOTE-716研究中无远处转移生存的最终分析
Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.
讲者：Jason J. Luke, MD, FACP | UPMC Hillman Cancer Center
摘要号：9508
替莫唑胺+顺铂vs特瑞普利单抗（抗PD-1）辅助治疗可切除的黏膜黑色素瘤
Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma.
讲者： 郭军 北京大学肿瘤医院
临床科学研讨会
摘要号：101
反应导向手术和辅助治疗对伊匹木单抗+纳武利尤单抗新辅助治疗III期黑色素瘤后长期生存的影响：PRADO和OpACIN-neo的3年数据
The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.
讲者：Irene L.M. Reijers, MD | Netherlands Cancer Institute
摘要号：2012
临床局限性黑色素瘤患者CNS转移危险因素的外部验证及列线图
External validation and nomogram for risk factors of CNS metastasis in patients with clinically localized melanoma.
讲者：
Merve Hasanov, MD | The University of Texas MD Anderson Cancer Center
壁报交流专场
摘要号：2015 | Poster Bd #372
来自经鞘内注射(IT)和静脉注射(IV) 纳武利尤单抗(N)治疗黑色素瘤伴软脑膜病(LMD)患者的脑脊液(CSF)纵向单细胞(sc)免疫谱分析
Longitudinal single-cell (sc) immune profiling of cerebrospinal fluid (CSF) from melanoma patients (pts) with leptomeningeal disease (LMD) treated with intrathecal (IT) and intravenous (IV) nivolumab (N).
讲者：Golnaz Morad, DDS, PhD | University of Texas MD Anderson Cancer Center
摘要号：2521 | Poster Bd #363
TLR9激动剂SD-101的压力赋能药物递送(PEDD)和免疫检查点抑制(ICI)在葡萄膜黑色素瘤肝转移(MUM)中的安全性和早期生物学效应：I期PERIO-01研究
Safety and early biologic effects of phase 1 PERIO-01 trial of pressure-enabled drug delivery (PEDD) of TLR9 agonist SD-101 and immune checkpoint inhibition (ICI) in uveal melanoma metastatic to the liver (MUM).
讲者：Kamaneh Montazeri, MD | Massachusetts General Hospital
摘要号： 9509 | Poster Bd #272
正在进行的I/II期IGNYTE研究中，RP1+纳武利尤单抗在抗PD-1失败的黑色素瘤患者中的初步疗效和安全性
Initial efficacy and safety of RP1 + nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study.
讲者：Bartosz Chmielowski, MD, PhD | Jonsson Comprehensive Cancer Center, University of California Los Angeles
摘要号：9510 | Poster Bd #273
Tunlametinib治疗晚期NRAS突变黑色素瘤患者的疗效和安全性：一项多中心、开放、单臂、II期研究
Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.
讲者： 斯璐 北京大学肿瘤医院
摘要号：LBA9512 | Poster Bd #275
隔离肝脏灌注治疗葡萄膜黑色素瘤肝转移的生存：随机对照SCANDIUM研究的结果
Survival after isolated hepatic perfusion as a treatment for uveal melanoma liver metastases: Results from a randomized controlled trial (the SCANDIUM trial).
讲者：Roger Olofsson Bagge, MD, PhD | Gothenburg University
摘要号：9513 | Poster Bd #276
从原发性和转移性葡萄膜黑色素瘤( UM )肿瘤中获取肿瘤浸润淋巴细胞( TIL )并进行体外扩增
Tumor infiltrating lymphocyte (TIL) harvest and ex vivo expansion from primary and metastatic (met) uveal melanoma (UM) tumors.
讲者：Sapna Pradyuman Patel, MD | The University of Texas MD Anderson Cancer Center
摘要号：9514 | Poster Bd #277
NeoPlus：仑伐替尼及帕博利珠单抗新辅助治疗可切除黏膜黑色素瘤的II期研究
NeoPlus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma.
讲者：毛丽丽 北京大学肿瘤医院
摘要号： LBA9515 | Poster Bd #278
基于循环肿瘤DNA的微小残留病作为使用mRNA-4157/V940、个性化癌症疫苗和帕博利珠单抗治疗的可切除高风险黑色素瘤患者无复发生存的生物标志物
Minimal residual disease by circulating tumor DNA as a biomarker of recurrence free survival in resected high-risk melanoma patients treated with mRNA-4157/V940, a personalized cancer vaccine, and pembrolizumab.
讲者：Matteo S. Carlino, PhD, FRACP, MBBS | Sydney Medical School, Faculty of Medicine and Health Sciences, University of Sydney, Camperdown and Melanoma Institute Australia, Sydney, NSW, Australia, and Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals
摘要号： 9516 | Poster Bd #279
基于干扰素γ特征在可切除的III期黑色素瘤中重新审视最佳新辅助免疫治疗方案：一项汇总分析
Revisiting the optimal neoadjuvant immunotherapy regimen in resectable stage III melanoma based on the interferon gamma signature: A pooled analysis.
讲者：Minke W. Lucas, MD | Netherlands Cancer Institute
摘要号：9517 | Poster Bd #280
晚期黑色素瘤治疗中，基于早期影像学评估的纳武利尤单抗和伊匹木单抗适应性剂量：一项II期研究( ADAPT-IT )的最终临床结果和首次转化相关因素
Final clinical results and first translational correlates of a phase 2 trial of adaptively dosed nivolumab and ipilimumab based on early radiographic assessment in advanced melanoma (ADAPT-IT).
讲者：James William Smithy, MD, MHS | Memorial Sloan Kettering Cancer Center
摘要号：9518 | Poster Bd #281
AJCC v8 IIIA期皮肤黑色素瘤患者（pts）中辅助治疗的疗效
Efficacy of adjuvant therapy in patients (pts) with AJCC v8 stage IIIA cutaneous melanoma.
讲者：Piyush Grover, MBBS, B.Pharm | Melanoma Institute Australia
摘要号：9520 | Poster Bd #283
纳武单抗维持治疗在纳武单抗和伊匹单抗联合治疗产生严重免疫相关不良事件的晚期黑色素瘤患者中的作用
Role of nivolumab maintenance therapy in advanced melanoma patients following severe immune-related adverse events from combination nivolumab and ipilimumab.
讲者：Anna Maloney, MPH | Frank H Netter MD School of Medicine
摘要号：12013 | Poster Bd #381
免疫检查点抑制对参与ECOG-ACRIN E1609辅助研究的黑色素瘤患者卵巢储备的影响
Impact of immune checkpoint inhibition on ovarian reserve in patients with melanoma enrolled in the ECOG-ACRIN E1609 adjuvant trial.
讲者：Elizabeth Iannotti Buchbinder, MD | Dana-Farber Cancer Institute
（本文依照报告日期和出场排序整理，如有错误或遗漏，敬请留言指正。）
https://meetings.asco.org/meetings/2023-asco-annual-meeting/299/program-guide/search?q=Melanoma
排版编辑：肿瘤资讯-Kate
苏公网安备32059002004080号
